Medical Establishment Wakes up to the Harms of Alzheimer’s Drugs

Medical establishment wakes up to the harms of Alzheimer’s drugs

Last week, a group of international researchers published a sobering verdict on the new generation of Alzheimer’s drugs. These treatments, the non-profit organisation Cochrane claims, “show no clinically meaningful effect” on memory, daily functioning or the overall course of the disease. The report reviewed 17 trials, each of which lasted more than a year, involving more than 20,000 patients. This class of drugs, known as anti-amyloids, was rej…

Major Independent Review Casts Doubt on Benefits of Leading Alzheimer's Drugs

A landmark analysis by the Cochrane Collaboration has found that the newest class of Alzheimer’s treatments offers benefits too small to make a real difference to patients — raising fresh questions for care homes about what lies ahead for residents living with dementia. A wide-ranging appraisal of clinical trial data has concluded that a new generation of Alzheimer’s treatments targeting a protein called amyloid beta produces benefits so small t…

Amyloid drugs for Alzheimer’s debate heats up - Medical Republic

Experts challenge the Cochrane findings, arguing newer Alzheimer’s therapies deliver modest but meaningful benefits, despite the review’s negative conclusions.

What did Cochrane say about Alzheimer’s amyloid drugs?

Cochrane review: no clinically meaningful benefit A newly published Cochrane review concludes that anti amyloid drugs for Alzheimer’s do not produce clinically meaningful effects for patients. The findings reignite a longstanding debate over whether amyloid targeting therapies deliver benefits…